Researcher comment: The 2-year outcomes of the DiRECT trial - Diabetes UK Professional Conference 2019; Liverpool, UK | diabetes.medicinematters.com
Skip to main content

Home

Latest news

Browse topics

Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN

In focus

Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management

Congress coverage

EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions

About us

Medicine Matters Diabetes
EXTENDED SEARCH
Log in
Top

03-07-2019 | Diet | Video | Article

Researcher comment: The 2-year outcomes of the DiRECT trial

share
SHARE
print
PRINT
insite
SEARCH

Roy Taylor explains why the DiRECT intervention may benefit a surprisingly wide variety of people, and how the trial’s findings could trigger a major shift in thinking about how to tackle type 2 diabetes (6:45).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

share
SHARE
print
PRINT
Image Credits